Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Neff, Guy [2 ]
Gunn, Nadege [3 ]
Flyer, Abigail [4 ]
MacConell, Leigh [5 ]
机构：
[1] Pinnacle Clin Res, San Antonio, TX USA
[2] Covenant Metab Specialists, Sarasota, FL USA
[3] Impact Res Inst, Waco, TX USA
[4] Pacific Northwest Stat Consulting, Woodinville, WA USA
[5] HighTide Therapeut, Rockville, MD USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-227
引用
收藏
页码：S614 / S615
页数：2
相关论文
共 50 条
  • [21] Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status
    Wallace, Hannah
    Wick, James
    Ketema, Daniel Bekele
    Neuen, Brendon Lange
    Jardine, Meg
    Lin Jialing
    Nelson, Craig L.
    Pearson, Sallie
    Peiris, David
    Woodward, Mark
    Ronksley, Paul E.
    Gallagher, Martin P.
    Kotwal, Sradha S.
    Jun, Min
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [22] Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a phase 2 trial
    Zhao, J.
    Zhao, M.
    Song, W.
    Wang, D.
    Zhang, X.
    Hui, Y.
    Zhou, Y.
    Lu, Y.
    Chen, H.
    Zhang, L.
    Cui, X.
    Wang, J.
    DIABETOLOGIA, 2024, 67 : S540 - S541
  • [23] Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study
    Houbachi, Lina
    Walker, Paul Michael
    Fournel, Isabelle
    Ksiazek, Elea
    Petit, Jean-Michel
    Cochet, Alexandre
    Leclercq, Thibault
    Roger, Antoine
    Simoneau, Isabelle
    Bouillet, Benjamin
    Guenancia, Charles
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 221
  • [24] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients
    Zhao, L.
    Wen, Q.
    Zhang, Y.
    Yu, G.
    Pan, T.
    Wang, Y.
    Li, F.
    Jin, P.
    Jiang, H.
    Zeng, M.
    Li, X.
    Li, X.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [25] EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM
    Selvarajah, Viknesh
    Robertson, Darren
    Hansen, Lars
    Jermutus, Lutz
    Smith, Kirsten
    Frickleton, Celeste
    Coggi, Angela
    Sanchez, Jose
    Chang, Yi-Ting
    Parker, Victoria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I87 - I87
  • [26] Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists A meta-analysis
    Dai, Danping
    Mao, Yiyang
    Jin, Haiying
    Zhang, Wei
    MEDICINE, 2019, 98 (36)
  • [27] WHEN AND HOW TO USE A GLP-1 RA WITH LONG-OR ULTRALONG-ACTING BASAL INSULIN IN T2DM
    Bode, Bruce
    ENDOCRINE PRACTICE, 2016, 22 : 14 - 22
  • [28] GLP-1 RECEPTOR AGONIST TREATMENT-RELATED FEATURES IMPORTANT TO TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS: A PREFERENCE STUDY IN GERMANY
    Qin, L.
    Chen, S.
    Shaunik, A.
    Flood, E.
    Romero, B.
    de la Cruz, M.
    Alvarez, C.
    Grandy, S.
    VALUE IN HEALTH, 2016, 19 (07) : A678 - A679
  • [29] Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 Inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 Diabetes Mellitus (T2DM) When Compared with Metformin Alone: A National Database Study
    Alaber, Omar A.
    Chandar, Apoorva K.
    Dahash, Basma A.
    Zuzek, Aleona C.
    Rajpal, Aman
    DIABETES, 2020, 69
  • [30] Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus
    Petrova, Lora
    Andreevska, Kalina
    Parvova, Iva
    Petkova, Valentina
    PHARMACIA, 2024, 71
12345